Intercept Pharma Europe Ltd.
$5.9M 0 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Currax Pharmaceuticals LLC
Currax Pharmaceuticals LLC reported $5,883,590.37 across General Payments, Research, and Ownership to 7,546 physicians and teaching hospitals across 8,655 transactions.
- $5.9M
- All-tracks total
- 8,655
- Transactions
- 7,546
- Recipients
- −$11.6K
- General Payments vs PY2023
Currax Pharmaceuticals LLC reported $5,883,590.37 across all CMS Open Payments tracks (General + Research + Ownership) to 7,546 physicians and teaching hospitals in Program Year 2024 - ranking #248 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $232,244.71, averaging $779.70 per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer currax-pharmaceuticals-llc Currax Pharmaceuticals LLC
$5.9M · #248/1,925 · 0.0% industry · PY2024
- TOT $5.9M
- RANK #248
- SHARE 0.0%
- TXN 8,655
- RCP 7,546
- CAT 3
- GEN $232.2K
- ΔGEN −$11.6K
- TOP1 7.3%
- PY 2024
Volume peers
Nearest volume peer: Intercept Pharma Europe Ltd. ($5.9M)
Currax Pharmaceuticals LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Currax Pharmaceuticals LLC's CMS-reported General Payments decreased by $11.6K (−4.7%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: CURRAX PHARMACEUTICALS LLCPY2023: CURRAX PHARMACEUTICALS LLCPY2024: Currax Pharmaceuticals LLC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $243,825.24
- PY2024
- $232,244.71
What the Data Shows for Currax Pharmaceuticals LLC
Currax Pharmaceuticals LLC ranks #248 out of 1,925 companies in the CMS Open Payments database for Program Year 2024, a comparatively small 0.0% slice of all industry payments reported nationwide for the year. The underlying total is $5,883,590.37 across 8,655 transactions to 7,546 physicians and teaching hospitals - $679.79 per transaction and $779.70 per recipient on average.
48 transactions worth $115.7K make "Consulting Fee" the top general-payment category in the 3-category breakdown below, 49.8% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Currax Pharmaceuticals LLC made 3 types of general payments. "Consulting Fee" is the largest category at $115.7K, 49.8% of General Payments.
How Currax Pharmaceuticals LLC divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $115.7K | 48 | 49.8% |
| Food and Beverage | $104.8K | 7,470 | 45.1% |
| Travel and Lodging | $11.7K | 28 | 5.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $59,474.38 (25.6%) of $232,244.71 in this company's General Payments records across 4,119 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Currax Pharmaceuticals LLC
The five named recipients with the highest reported General Payments from this company
- 1
Angela Kay Fitch
$17,004.41 across 14 reported transactions
- 2
James Davis
$11,750.00 across 3 reported transactions
- 3
Milton Lethan Pressler
$11,040.00 across 3 reported transactions
- 4
Angela K Golden
$10,061.19 across 15 reported transactions
- 5
Anthony Auriemma
$9,618.78 across 18 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Currax Pharmaceuticals LLC's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Currax Pharmaceuticals LLC.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Currax Pharmaceuticals LLC.
Showing 6 of 1,924 companies with CMS-reported payment data.
Renalytix AI, Inc.
$5.9M 1,559 recipients
Compare payment profiles
Ipsen Innovation
$5.8M 124 recipients
Compare payment profiles
Zimvie Inc.
$5.9M 45,653 recipients
Compare payment profiles
Ventana Medical Systems, Inc.
$5.9M 69 recipients
Compare payment profiles
OMNIlife science, Inc
$5.8M 829 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.